CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Exclusion Criteria

• •Any prior treatment for breast cancer
• •Metastatic disease (M1)
• •Performance status (ECOG) \> or = 3
• •Current malignancy or history of prior malignancy within past 10 years (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ of the uterine cervix)
• •Neutrophils \< 2.000/mm³ , platelets \< 100.000/mm³ , hemoglobin \< 10 g/dl.
• •Creatinine \> 1.25 x the upper normal limit
• •GOT and/or GPT and/or bilirubin \>1.25 x the upper normal limit.
• •Concomitant conditions that, in the investigator's opinion, contraindicate the use of the drugs in the protocol.
• •Congestive heart failure or history of congestive heart failure, unstable angina pectoris, myocardial infarction, clinically significant valvulopathy or uncontrolled arrhythmias
• •Active infection
• •Incapacity or refusal to provide informed consent.
• •Inability to comply with follow up
• •Pregnant or nursing females.